Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04400292 · ClinicalTrials.gov registry record · NA

Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

A NA study of Esophageal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT04400292: Active NA study of Esophageal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04400292 is a NA study of Esophageal Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 90 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04400292, a NA study of Esophageal Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.

Primary Outcome

Surgical data will include the number of lymph nodes identified and removed both NIRfluorescent and NIR-nonfluorescent nodes.

Conditions Studied

Interventions

  • OTHER Injection of indocyanine green (ICG)dye
  • DEVICE Near-Infrared Image-Guided
  • PROCEDURE Sentinel Lymph Node (SLN) mapping

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2020-05-20
Est. Completion 2026-05
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04400292 still lists

NCT04400292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Injection of indocyanine green (ICG)dye is the first listed.

NCT04400292 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04400292 about?

NCT04400292 is a clinical study titled "Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging". The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future coul...

What is the current status of trial NCT04400292?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2020-05-20. Estimated completion is 2026-05.

What conditions does trial NCT04400292 study?

This clinical trial studies the following conditions: Esophageal Cancer.

What interventions are being tested in trial NCT04400292?

The interventions under investigation include: Injection of indocyanine green (ICG)dye (OTHER), Near-Infrared Image-Guided (DEVICE), Sentinel Lymph Node (SLN) mapping (PROCEDURE).

Who is sponsoring clinical trial NCT04400292?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04400292 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04400292's enrollment target sits among peer trials

90 60th of 123 higher than 63 of 123 other Esophageal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04400292, the US trial registry maintained by the National Library of Medicine. NCT04400292 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.